Comment: PD-1 targeting MK-3475 gives long-term responses in

2014 ASCO Annual Meeting

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma

Listen now

Description

At ASCO 2014, Dr O'Day provides ecancertv with his expert opinion on the findings from a large phase I study of 411 patients with advanced melanoma which showed that the PD-1 targeting antibody MK-3475 yields long-term responses in a high percentage of patients.

More Episodes

See all »

2014 ASCO Annual Meeting

Published 07/15/14

ASCO 2014 roundup

ecancer's Prof McVie provides a roundup of the main points of discussion from ASCO 2014.

Published 07/11/14

KRAS/NRAS and BRAF mutations in study of panitumumab plus FOLFIRI for second-line treatment of mCC

Prof Peeters talks to ecancertv at ASCO 2014 about the updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab plus FOLFIRI for second-line treatment of metastatic colorectal cancer.

Published 07/11/14